MARCoNI assay shows resveratrol binds ER-alpha
Researchers at The Scripps Research Institute recently published key findings in eLIFE, that revealed "molecular secrets" behind Resveratrol's health benefits. They found that resveratrol controls the bodys inflammatory response as a binding partner with the estrogen receptor without stimulating estrogenic cell proliferation. PamGene's MARCoNI assay contributed in revealing key insights in this process.

According to the new study, resveratrol inhibits IL-6 a pro-inflammatory protein that is part of the immune system, without stimulating cell proliferation by altering a number of co-regulators of the estrogen receptor.  In the unraveling of the molecular mechanisms, the MARCoNI assay was used to analyze ligand-induced binding of over 150 distinct, nuclear receptor-interacting, coregulator peptide motifs to the ERα LBD, including those derived from both coactivators and corepressors.  Results suggested that resveratrol binds the ERα LBD, and induces an altered AF2 surface, which reduces affinity for most coregulator peptides, but enables selectivity in the context of full-length receptor and coregulators.

Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. 
Nwachukwu JC, Srinivasan S, Bruno NE, Parent AA, Hughes TS, Pollock JA, Gjyshi O1, Cavett V, Nowak J, Garcia-Ordonez RD, Houtman R, Griffin PR, Kojetin DJ, Katzenellenbogen JA, Conkright MD, Nettles KW. Elife. 2014 Apr 25;3:e02057. doi: 10.7554/eLife.02057.

Read the full article

Figure DOI: